Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Annals of Nuclear Medicine

• Publication date

  2019-03-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12149-019-01354-9PMID 30929200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility

  2018cited by this paper
• A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial

  2018cited by this paper
• Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

  2018cited by this paper
• Update on mantle cell lymphoma.

  2018cited by this paper
• Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma

  2018cited by this paper
• Metabolic Tumor Volume Metrics in Lymphoma.

  2018cited by this paper
• Prognostic role of baseline 18F‐FDG PET/CT parameters in MALT lymphoma

  2018cited by this paper
• Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma

  2018cited by this paper
• Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt’s lymphoma: the role of Deauville and IHP criteria

  2018cited by this paper
• WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

  2017cited by this paper
• 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine–Rituximab

  2017cited by this paper
• Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

  2017cited by this paper
• Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

  2017cited by this paper
• Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

  2016cited by this paper
• Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy

  2016cited by this paper
• Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL

  2016cited by this paper
• Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings

  2015cited by this paper
• Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

  2014cited by this paper
• Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma?

  2014cited by this paper
• Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma

  2014cited by this paper
• Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

  2014cited by this paper
• FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

  2014cited by this paper
• Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

  2014cited by this paper
• Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants

  2014cited by this paper
• Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes.

  2014cited by this paper
• Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma

  2013cited by this paper
• Post‐treatment (not interim) positron emission tomography‐computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R‐HyperCVAD

  2012cited by this paper
• Current Management of Mantle Cell Lymphoma

  2012cited by this paper
• Utility of positron emission tomography scans in mantle cell lymphoma

  2011cited by this paper
• Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma.

  2011cited by this paper
• Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study

  2011cited by this paper
• Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group

  2010cited by this paper
• 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients

  2010cited by this paper
• Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

  2010cited by this paper
• Proliferation predicts failure‐free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high‐dose methotrexate and cytarabine

  2009cited by this paper
• FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome

  2009cited by this paper
• Outcome of deferred initial therapy in mantle-cell lymphoma.

  2009cited by this paper
• [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.

  2008cited by this paper
• Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

  2008cited by this paper
• Positron emission tomography in mantle cell lymphoma

  2008cited by this paper
• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

  2006cited by this paper
• The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.

  2006cited by this paper
• Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.

  2005cited by this paper
• Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

  2005cited by this paper
• Biology and management of mantle cell lymphoma

  2001cited by this paper
• Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype

  2001cited by this paper
• Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood.

  1990cited by this paper

• Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

  2024cites this paper
• Enhancing Prognostication and Treatment Response Evaluation in Primary CNS Lymphoma with 18F-FDG PET/CT.

  2024cites this paper
• Radiomics predictive modeling from dual-time-point FDG PET Ki parametric maps: application to chemotherapy response in lymphoma

  2023cites this paper
• The diagnostic value of dual-layer CT in the assessment of lymph nodes in lymphoma patients with PET/CT as a reference standard

  2023cites this paper
• Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial

  2023cites this paper
• Clinical Application of 18F-FDG-PET Quantification in Hematological Malignancies: Emphasizing Multiple Myeloma, Lymphoma and Chronic Lymphocytic Leukemia.

  2023cites this paper
• Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)

  2022cites this paper
• Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma

  2022cites this paper
• Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma

  2022influential citation
• Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma

  2022cites this paper
• Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

  2022cites this paper
• Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma

  2022cites this paper
• Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?

  2022cites this paper
• Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

  2022cites this paper
• Prospective Evaluation of Different Methods for Volumetric Analysis on [18F]FDG PET/CT in Pediatric Hodgkin Lymphoma

  2022cites this paper
• Longitudinal Body Composition Changes Detected by [18F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma

  2022cites this paper
• [18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma

  2022cites this paper
• Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?

  2022cites this paper
• Metabolic tumour volume on 18F-FDG PET/CT predicts extended pathological T stages in patients with renal cell carcinoma at staging

  2021cites this paper
• The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma.

  2021cites this paper
• Evaluation of an Automatic Classification Algorithm Using Convolutional Neural Networks in Oncological Positron Emission Tomography

  2021cites this paper
• The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review

  2021cites this paper
• Prognostic Impact of Pretreatment 2-[18F]-FDG PET/CT Parameters in Primary Gastric DLBCL

  2021cites this paper
• Value of baseline and end of chemotherapy 18F-FDG PET/CT in pediatric patients with Burkitt lymphoma

  2021cites this paper
• Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate‐risk Hodgkin lymphoma treated with chemo‐radiation therapy: FDG‐PET parameter analysis in a subgroup from COG AHOD0031

  2021cites this paper
• Correlation of 18F-FDG PET/CT SUVmax with clinical features, D-dimer and LDH in patients with primary intestinal lymphoma

  2021cites this paper
• The optimal use of PET/CT in the management of lymphoma patients.

  2021cites this paper
• 18F-FDG-PET/CT in laryngeal cancer: Comparison with conventional imaging and prognostic role.

  2021cites this paper
• Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

  2020cites this paper
• Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients

  2020cites this paper
• 2-[18F]-FDG PET/CT Role in Detecting Richter Transformation of Chronic Lymphocytic Leukemia and Predicting Overall Survival.

  2020cites this paper
• 18F-FDG PET or PET/CT in Mantle Cell Lymphoma.

  2020cites this paper
• 18F-FDG PET/CT role in Burkitt lymphoma

  2020cites this paper
• Prognostic value of 18F-FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

  2020cites this paper
• Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Splenic Marginal Zone Lymphoma.

  2020cites this paper
• 18F-FDG-PET/CT in laryngeal cancer: comparison with conventional imaging and prognostic role.

  2020cites this paper
• Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.

  2020cites this paper
• Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

  2020cites this paper
• The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas

  2020cites this paper
• The PET-Derived Tumor-to-Liver Standard Uptake Ratio (SUVTLR) Is Superior to Tumor SUVmax in Predicting Tumor Response and Survival After Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer

  2020cites this paper
• Metabolic behavior and prognostic role of pretreatment 18F‐FDG PET/CT in gist

  2020cites this paper
• Utility of [18F] Fluoro-Deoxyglucose Positron Emission Tomography/Computed Tomography for Staging and Therapy Response Evaluation in Pediatric Rhabdomyosarcoma: A Case Series and Literature Review

  2020cites this paper
• The Incremental Prognostic Value of Baseline 18F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma

  2020cites this paper
• Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma

  2020cites this paper
• Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma

  2019cites this paper
• Diagnostic and Clinical Impact of Staging 18F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience.

  2019cites this paper
• The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study

  2019cites this paper
• Prognostic value of baseline 18F‐FDG PET/CT metabolic parameters in paediatric lymphoma

  2019cites this paper
• Prognostic Value of 18F-FDG PET/CT-Metabolic Parameters at Baseline and Interim Assessment in Pediatric Anaplastic Large Cell Lymphoma.

  2019cites this paper